On October 2, 2026, FMR LLC acquired 3.52 million shares of GENSCRIPT BIO (01548) on the SEHK open market at an average of HKD 43.2187 per share, involving approximately HKD 151.96 million. The transaction was an on-exchange active trade, representing a direct dealing in the secondary market.
Prior to the acquisition, FMR LLC's long position in GENSCRIPT BIO was 133.45 million shares, representing 5.85%; following the acquisition, the holding changed to 136.97 million shares, with the long position ratio rising to 6.01%.